Clinical trial
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
NCT00273936 · Vertex Pharmaceuticals Incorporated, Industry · Completed
Key facts
| NCT number | NCT00273936 |
|---|---|
| Title | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies |
| Official title | A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | AVN-944 capsules for oral administration |
| Enrollment | 72 |
| Start date | Jan 1, 2006 |
| First posted | Jan 10, 2006 |
| Last update posted | Aug 4, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: